When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved ...

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung ...

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

An international study, significantly shaped by Greek oncology, has unveiled a promising new treatment for small cell lung ...

Key secondary end points included intracranial cORR, duration of response (DOR), progression-free survival (PFS), and safety ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...

Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response ...